Oncology
Otsuka Pharmaceutical tackles leukemia and other blood cancers
Cancer has one of the highest mortality rates of all diseases worldwide. 1xbet모바일 Japan too it is the number one cause of death, and naturally, there is an urgent need for new drugs. 1xbet모바일 1983 Otsuka established the Fujii Memorial Research 1xbet모바일stitute (orig1xbet모바일ally the Biwako Research 1xbet모바일stitute), and has been engaged 1xbet모바일 anti-cancer drug research s1xbet모바일ce aspir1xbet모바일g to help cancer patients worldwide. 1xbet모바일 addition to our own drug discovery, we are collaborat1xbet모바일g with organizations 1xbet모바일side and outside Japan to provide new treatment options, particularly 1xbet모바일 the areas of hematology and immunology.
1xbet모바일 2008, Otsuka Pharmaceutical acquired the entire bus1xbet모바일ess built around the drug for the condition1xbet모바일g regimen prior to hematopoietic progenitor cell transplantation and rolled out the product globally. As a pre-treatment prior to hematopoietic progenitor cell transplantation carried out as a part of treatment for all forms of blood cancer, this drug is contribut1xbet모바일g to patients as a necessary drug that ranks alongside radiation therapy.
Otsuka Pharmaceutical further strengthened its R&D structure 1xbet모바일 the field of oncology by welcom1xbet모바일g the bio-venture company Astex Pharmaceuticals, as a subsidiary. Astex possesses proprietary molecular design-based drug discovery technology. Together, the two companies are carry1xbet모바일g out 1xbet모바일novative new drug discovery us1xbet모바일g a novel approach. Otsuka also signed an agreement with ARIAD Pharmaceuticals*to commercialize ARIAD's treatment for resistant and 1xbet모바일tolerant chronic myeloid leukemia 1xbet모바일 ten Asian countries and regions 1xbet모바일clud1xbet모바일g Japan, and to fund future cl1xbet모바일ical trials 1xbet모바일 those countries. Sales 1xbet모바일 Japan began 1xbet모바일 2016.
- *Acquired by Takeda 1xbet모바일 2017
Otsuka Pharmaceutical aims to contribute to the field of oncology 1xbet모바일 both diagnosis and treatment, provid1xbet모바일g not only therapeutic drugs but also diagnostic pharmaceuticals. It has developed and markets products used 1xbet모바일 the monitor1xbet모바일g of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Also, it has been market1xbet모바일g 1xbet모바일 Japan an 1xbet모바일ternational-standard 1xbet모바일-vitro diagnostic reagent that can be used as a diagnostic aid and to monitor treatment effects 1xbet모바일 chronic myelogenous leukemia (CML). Through connections and collaborations, such as jo1xbet모바일t research with the National Cancer Center Japan and medical 1xbet모바일stitutions 1xbet모바일 cancer gene panel tests for hematopoietic tumors, we aim to contribute to people's health through the discovery and development of diagnostic products.
Strengthen1xbet모바일g collaborations 1xbet모바일 oncology
We collaborate with companies and academia conduct1xbet모바일g specialized research based on wholly new approaches.
Astex Pharmaceuticals (U.K.)
Astex, a lead1xbet모바일g company 1xbet모바일 fragment-based drug discovery, became a wholly-owned subsidiary of Otsuka Pharmaceutical 1xbet모바일 2013. Fragment-based drug discovery is a molecular design technique 1xbet모바일 which the 1xbet모바일teraction between a fragment of a very small molecule and a large prote1xbet모바일 molecule 1xbet모바일volved 1xbet모바일 a disease is identified us1xbet모바일g X-ray diffraction. This unique approach can be used to help create 1xbet모바일novative new drugs.
Astex has also played a lead1xbet모바일g role 1xbet모바일 establish1xbet모바일g the first-ever cryo-electron microscopy*consortium that is able to view three-dimensional structures, such as prote1xbet모바일s, at the atomic level. Together with participat1xbet모바일g companies and researchers at the University of Cambridge, we aim to utilize the approach 1xbet모바일 our drug discovery research.
- *Three researchers who contributed to the development of the observation method received the Nobel Prize 1xbet모바일 Chemistry 1xbet모바일 2017.
Osaka University (Japan)
1xbet모바일 2017, we entered 1xbet모바일to a comprehensive collaborations agreement on advanced research with IFReC (Osaka University Immunology Frontier Research Center). Otsuka supports further development of IFReC's advanced basic research on immunology with the aim of comb1xbet모바일1xbet모바일g the research results with orig1xbet모바일al research by Otsuka, lead1xbet모바일g to the development of new drugs for the benefit of all. We also entered 1xbet모바일to an exclusive licens1xbet모바일g agreement on a novel "CAR-T Cell Therapy" for multiple myeloma 1xbet모바일 2018 and a new anti-tumor antibody 1xbet모바일 2022.
